bumetanide has been researched along with Anterior Choroidal Artery Infarction in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data suggest that bumetanide exerts its neuroprotective and anti-edema effects partly via blockade of the perivascular pool of AQP4 and may have therapeutic potential for ischemic stroke in the clinical setting." | 3.76 | Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4. ( Adams, ME; Amiry-Moghaddam, M; Bhardwaj, A; Froehner, SC; Migliati, ER; Ottersen, OP, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Donnell, ME | 1 |
| Lam, TI | 1 |
| Tran, L | 1 |
| Anderson, SE | 1 |
| Migliati, ER | 1 |
| Amiry-Moghaddam, M | 1 |
| Froehner, SC | 1 |
| Adams, ME | 1 |
| Ottersen, OP | 1 |
| Bhardwaj, A | 1 |
| Yan, Y | 2 |
| Dempsey, RJ | 2 |
| Flemmer, A | 1 |
| Forbush, B | 1 |
| Sun, D | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study[NCT03000283] | Phase 1 | 7 participants (Actual) | Interventional | 2017-03-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in cerebral edema (CE) as measured on CT. Goal is a -5 to -10% change in CE over time. Change will be measured both as absolute change in volume, calculated as the final volume minus the baseline volume measure and converted to a percentage of the baseline volume measure. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Conivaptan Treatment Group | -37.1 |
Cost as measured by length of stay in the neuro ICU. (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | days (Mean) |
|---|---|
| Conivaptan Treatment Group | 14.4 |
All-cause deaths during hospitalization (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Conivaptan Treatment Group | 0 |
Modified Rankin Scale (0 to 6) at discharge from the hospital. A score of 0 indicates no disability and a score of 6 indicates the patient died. Functional independence is defined as a score of 2 or less. (NCT03000283)
Timeframe: At discharge from ICU and from hospital, up to 3 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Conivaptan Treatment Group | 5 |
"Cost as measured by:~Need for external ventricular drain (EVD)/bolt or surgical procedures (craniectomy, clot evacuation,VPS) for reduction/management of CE.~Need for central venous lines, arterial lines, peripherally inserted central venous catheter (PICC) lines, tracheostomy/percutaneous endoscopic gastrostomies (PEGs).~Number of patients requiring a ventilator." (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| EVD/bolt or surgical procedures | Lines or tracheostomy/PEG | Ventilator | |
| Conivaptan Treatment Group | 0 | 7 | 1 |
The number of participants with abnormal seizure activity and/or abnormal lab values and/or increase in infection rate and/or any drug-related adverse events. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Abnormal Seizure Activity | Abnormal Lab Values | Infections | Drug-related Adverse Events | |
| Conivaptan Treatment Group | 0 | 0 | 1 | 0 |
4 other studies available for bumetanide and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
The role of the blood-brain barrier Na-K-2Cl cotransporter in stroke.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Edema; Brain Ischemia; Bumetanide; Cerebral Infarcti | 2004 |
Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4.
Topics: alpha-Synuclein; Animals; Aquaporin 4; Brain Edema; Bumetanide; Cerebral Infarction; Male; Mice; Mic | 2010 |
Inhibition of Na(+)-K(+)-Cl(-) cotransporter during focal cerebral ischemia decreases edema and neuronal damage.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Bumetanide; Cerebral Infarction; Drug Administration Sc | 2003 |
Na+-K+-Cl- cotransporter in rat focal cerebral ischemia.
Topics: Animals; Astrocytes; Autoradiography; Brain Chemistry; Brain Edema; Bumetanide; Carrier Proteins; Ce | 2001 |